2024 / 04

Next Paper
DOI: 10.24075/rbh.2024.112
Copyright: © 2024 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).

REVIEW

Hygienic aspects of human carcinogenic safety with respect to biological factors

Eliseev YuYu, Chekhomov SYu, Eliseeva YuV
About authors

Saratov State Medical University, Saratov, Russia

Correspondence should be addressed: Yuri Yu Eliseev
B. Kazachya, 112, Saratov, 410012, Russia; ur.liam@55veesiley

About paper

Author contribution: Eliseev YuYu — literature search, manuscript authoring, article editing and discussion; Chekhomov SYu — literature data analysis, results interpretation, approval of the final version of the article; Eliseeva YuV — data analysis and interpretation, authoring, article editing and discussion.

Received: 2024-04-22 Accepted: 2024-06-27 Published online: 2024-12-02
|
  1. Onishhenko GG. Rol' gosudarstvennoj sanitarno-jepidemiologicheskoj sluzhby Rossii v zashhite zdorov'ja naselenija. Zdravoohranenie Rossijskoj Federacii. 2013; (2): 3–9 (in Rus.).
  2. Gurvich VB, Kuzmin SV, Kuzmina EA, Jarushin SV, Adrianovskij VI, Lipatov GJa, et al. K voprosu aktualizacii osnovnyh polozhenij SanPin 1.2.2353-08 "Kancerogennye faktory i osnovnye trebovanija k profilaktike kancerogennoj opasnosti". Medicina truda i promyshlennaja jekologija. 2018; (11): 46–51 (in Rus.). DOI: 10.31089/1026-9428-2018-11-46-51.
  3. Pivovarova EA, Shibanova NJu. Ocenka kancerogennogo riska zdorov'ju naselenija Respubliki Hakassija, obuslovlennogo potrebleniem pit'evoj vody. Analiz riska zdorov'ju. 2016; (3): 44–52 (in Rus.). DOI: 10.21668/health.risk/2016.3.05.
  4. Anoshkina EV, Andreeva EV, Sainova VN. Sistema rannego preduprezhdenija posledstvij zagrjaznenija atmosfery v analize kancerogennyh riskov. Fundamental'nye issledovanija. 2014; 11 (5): 1032–4 (in Rus.).
  5. Kurolap SA, Klepikov OV, Kulnev VV, Kizeev AN, Sjurin SA, Enin АV. Kancerogennyj risk, svjazannyj s zagrjazneniem atmosfernogo vozduha promyshlennyh gorodov Central'nogo Chernozem'ja. Gigiena i sanitarija. 2023; 102 (8): 853–60 (in Rus.). DOI: 10.47470/0016-9900-2023-102-8-853-860.
  6. Klejn SV, Vekovshinina SA, Balashov SJu, Horoshavin VA, Uhabov VM. Gigienicheskaja ocenka kancerogennogo riska zdorov'ju naselenija, prozhivajushhego v zone vlijanija mest skladirovanija othodov gorno-obogatitel'nogo kombinata: 2014–2017 gg. Gigiena i sanitarija. 2017; 97 (1): 10–15 (in Rus.). DOI: 10.18821/0016-9900-2018-97-1-10-15.
  7. Revazova JuA, Iljushina NA. K voprosu o negenotoksicheskih kancerogenah. Toksikologicheskij vestnik. 2021; 29 (4): 51–5 (in Rus.). DOI: 10.36946/0869-7922-2021-29-4-51-55.
  8. Babanov SA, Budash DS, Bajkova AG, Ryzhova NS. Professional'nye zlokachestvennye novoobrazovanija legkih i drugih lokalizacij i potencial'no opasnye proizvodstvennye kancerogeny. Consilium Medicum. 2017; 19 (11): 39–46 (in Rus.). DOI: 10.26442/2075-1753_19.11.39-46.
  9. Ivanov (Kolokolcov) MN. Transplacentarnyj kancerogenez, vyzvannyj policiklicheskimi aromaticheskimi uglevodorodami. Uspehi sovremennogo estestvoznanija. 2007; 12 (1): 51–2 (in Rus.).
  10. Leshhenko JaA, Lisovcov AA. Smertnost' kak indikator sanitarno-jepidemiologicheskogo statusa naselenija regiona. Gigiena i sanitarija. 2021; 100 (12): 1495–501 (in Rus.). DOI: 10.47470/0016-9900-2021-100-12-1495-1501.
  11. Sanitarnye pravila i normy SanPiN 1.2.3685-21 "Gigienicheskie normativy i trebovanija k obespecheniju bezopasnosti i (ili) bezvrednosti dlja cheloveka faktorov sredy obitanija". Postanovlenie Rospotrebnadzora ot 28.01.2021 № 2.
  12. Oikonomopoulou K, Brinc D, Kyriacou K, Diamandis EP. Infection and cancer: revaluation of the hygiene hypothesis. Clin Cancer Res. 2013; 19 (11): 2834–41. DOI: 10.1158/1078-0432.CCR-12-3661.
  13. Fernandes R, Alves H, Botelho MC. The cancer hygiene hypothesis: from theory to therapeutic helminths. Curr Cancer Ther Rev. 2019; 15 (3): 248–50. DOI: 10.2174/1573394714666181003143717.
  14. Kaprin AD, Starinskij VV, Petrova GV, redaktory. Sostojanie onkologicheskoj pomoshhi naseleniju Rossii v 2018 godu. M.: MNIOI im. P. A. Gercena — filial FGBU «NMIC radiologii» Minzdrava Rossii, 2019; 236 p. (in Rus.).
  15. Kaprin AD, Starinskij VV, Petrova GV, redaktory. Sostojanie onkologicheskoj pomoshhi naseleniju Rossii v 2019 godu. M.: MNIOI im. P. A. Gercena — filial FGBU "NMIC radiologii" Minzdrava Rossii, 2020; 239 p. (in Rus.).
  16. Rabochaja gruppa MAIR po ocenke kancerogennyh riskov dlja ljudej. Biologicheskie agenty. Obzor chelovecheskih kancerogenov. IARC Monogr Eval Carcinog Risks Hum. 2012; 100 (Pt B): 1–441.
  17. Im SA, Lu YS, Bardia A, Harbeck N, Colleoni M, Franke F, et al. Overall survival with Ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019; 381 (4): 307–16. DOI: 10.1056/NEJMoa1903765.
  18. Loibl S, Turner NC, Ro J, Cristofanilli M, Iwata H, Im SA, et al. Palbociclib combined with Fulvestrant in premenopausal women with advanced breast cancer and prior progression on endocrine therapy: PALOMA-3 results. Oncologist. 2017; 22 (9): 1028–38. DOI: 10.1634/theoncologist.2017-0072.
  19. Glushkov AN. Kancerogenez: osnovnye ponjatija, istochniki i klassifikacija kancerogenov. Medicina v Kuzbasse. 2003; (2): 8–12 (in Rus.).
  20. Konstitucija Rossijskoj Federacii: [prinjata vsenarodnym golosovaniem 12 dekabrja 1993 g. s izmenenijami, odobrennymi v hode obshherossijskogo golosovanija 01 ijulja 2020 g.]. (In Rus.).
  21. Federal'nyj zakon ot 10.01.2002 (s izm. ot 2 ijulja 2013 g.) № 7-FZ "Ob ohrane okruzhajushhej sredy"). (In Rus.).
  22. Federal'nyj zakon ot 30.03.1999 (v red. ot 13.07.2020) № 52-FZ "O sanitarno-jepidemiologicheskom blagopoluchii naselenija" (In Rus.).
  23. Matusevich VA, Stukolova IV. Rol' virusov v kancerogeneze [Internet]. 2024 [cited 2024 Feb 20]. URL: https://omr.by/news/stati/rol-virusov-v-kantserogeneze.
  24. Chubenko VA. Virus-associirovannye opuholi s tochki zrenija klinicista: ot jepidemiologii do lechenija. Prakticheskaja onkologija. 2018; 19 (4): 311–23 (in Ris.).
  25. Nyberg AH, Sadikova E, Cheetham C, Chiang KM, Shi JX, Caparosa S, et al. Increased cancer rates in patients with chronic hepatitis C. Liver International. 2020; 40 (3): 685–93.
  26. Sherifova AI, Parsadanjan AM. Obzor prediktorov razvitija raka pecheni. Kreativnaja hirurgija i onkologija. 2023; 13 (3): 229–37 (in Rus.). DOI: 10.24060/2076-3093-2023-13-3-229-237.
  27. de Cremoux P, de la Rochefordière A, Savignoni A, Kirova Y, Alran S, Fourchotte V, et al. Different outcome of invasive cervical cancer associated with high-risk versus intermediate-risk HPV genotype. Int J Cancer. 2009; 124 (4): 778–82.
  28. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010; 11 (11): 1048–56. DOI: https://doi.org/10.1016/S1470-2045(10)70230-8.
  29. Volgareva GM. Papillomovirusnyj kancerogenez. Osnovnye dostizhenija i nekotorye problemy. Chast' 1. Obshhie predstavlenija o papillomavirusah. Formy raka, associirovannye s virusami papillomy cheloveka. Rossijskij bioterapevticheskij zhurnal. 2020; 9 (1): 6–12 (in Rus.).
  30. Volgareva GM. Papillomovirusnyj kancerogenez. Osnovnye dostizhenija i nekotorye problemy. Chast' 2. VPCh-associirovannye formy raka v Rossii. Profilakticheskie VPCh-vakciny. Rossijskij bioterapevticheskij zhurnal. 2020; 19 (2): 31–8 (in Rus.).
  31. Kostin AA. Analiz statisticheskih dannyh o zlokachestvennyh novoobrazovanijah, associirovannyh s virusom papillomy cheloveka. Research'n Practical Medicine Journal. 2016; 3 (1): 66–78 (in Rus.).
  32. Champer M, Wong AM, Champer J, Brito IL, Messer PW, Hou JY, et al. The role of the vaginal microbiome in gynaecological cancer. J Obstet Gynaecol. 2018; 125 (3): 309–15. DOI: 10.1111/1471-0528.14631.
  33. Shestakova IV, Jushhuk ND. Rol' virusa Jepshtejna-Barr v onkogeneze. Rossijskij mediko-biologicheskij vestnik imeni akademika I. P. Pavlova. 2014; (3): 75–85 (in Rus.).
  34. Roschewski M, Wilson WH. EBV-associated lymphomas in adults. Best Pract Res Clin Haematol. 2012; 25 (1): 75–89.
  35. Isakov VA. Gerpesvirusnye infekcii cheloveka: rukovodstvo dlja vrachej. 2-e izd., pererab. i dop. Sankt-Peterburg: SpecLit, 2013; 670 p. (in Rus.).
  36. Alieva EI, Antonova AO, Verhovskaja MD. Verhovskaja Virusnyj kancerogenez. Obzor literatury po probleme. Vestnik Cheljabinskogo gosudarstvennogo universiteta. Obrazovanie i zdravoohranenie. 2021; 4 (16): 60–6 (in Rus.).
  37. Mahieux R, Gessain A. HTLV-3/STLV-3 and HTLV-4 viruses: discovery, epidemiology, serology and molecular aspects. Viruses. 2011; 3 (7): 1074–90. DOI: 10.3390/v3071074.
  38. Gurcevich VJe. Onkogennye virusy cheloveka: ot latentnogo virusonositel'stva k kancerogenezu. Voprosy onkologii. 2005; (1): 8–12 (in Rus.).
  39. Susova OJu, Gurcevich VJe. Oblast' RH HTLV-1 v zhiznennom cikle virusa i kancerogeneze. Molekuljarnaja biologija. 2003; 37 (3): 1–12 (in Rus.).
  40. Syrcev AV. Virus T-kletochnogo lejkoza cheloveka (HTLV-1) u seronegativnyh pacientov s limfomami kozhi, klassicheskim lejkozom i bessimptomnyh nositelej v Rossii. Molekuljarnaja medicina. 2009; (6): 25–32 (in Rus.).
  41. Tan BJ, Sugata K, Reda O, Matsuo M, Uchiyama K, Miyazato P, et al. HTLV-1 infection promotes excessive T cell activation and transformation into adult T cell leukemia/lymphoma. J Clin Invest. 2021; 131 (24): e150472. DOI: 10.1172/JCI150472.
  42. DeMichele A, Cristofanilli M, Brufsky A, Liu X, Mardekian J, McRoy L, et al. Comparative effectiveness of firstline palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice. Breast Cancer Res. 2021; 23 (1): 37. DOI: 10.1186/s13058-021-01409-8.
  43. Gao JJ, Cheng J, Bloomquist E, Sanchez J, Wedam SB, Singh H, et al. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. Lancet Oncol. 2020; 21 (2): 250–60. DOI: 10.1016/S1470-2045(19)30804-6.
  44. Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020; 31 (12): 1623–49. DOI: 10.1016/j.annonc.2020.09.010.
  45. Giuliano M, Schettini F, Rognoni C, Milani M, Jerusalem G, Bachelot T, et al. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Lancet Oncol. 2019; 20 (10): 1360–9. DOI:10.1016/S1470-2045(19)30420-6.
  46. Wang L, Gao S, Li D, Ran X, Sheng Z, Wu W, et al. CDK4/6 inhibitors plus endocrine therapy improve overall survival in advanced HR+/HER2- breast cancer: a meta-analysis of randomized controlled trials. Breast J. 2020; 26 (7): 1439–43. DOI: 10.1111/tbj.13703.
  47. Mamedov MK, Dadasheva AJe, Kadyrova AA. Onkologicheskie aspekty, vyzvannye virusom immunodeficita cheloveka. Biomedicina. 2006; (3): 3–10 (in Rus.).
  48. Nekrasova AV, Rassohin VV, Falaleeva NA, Grivcova LJu, Gusev DA. Zlokachestvennye novoobrazovanija u VICh-inficirovannyh pacientov v Rossii: istorija srokom v 20 let. Sovremennaja onkologija. 2021; 23 (4): 593–7 (in Rus.). DOI: 10.26442/18151434.2021.4.201291.
  49. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7–14 June 1994. IARC Monogr Eval Carcinog Risks Hum. 1994; (61): 1–241.
  50. Osadchuk AM, Davydkin IL, Gricenko TA, Osadchuk MA. Obshhie i chastnye voprosy jetiopatogeneza jazvennoj bolezni i raka zheludka: sovremennoe sostojanie problemy. Terapevticheskij arhiv. 2020; 92 (2): 97–103 (in Rus.).
  51. Ansari S, Yamaoka Y. Helicobacter pylori virulence factors exploiting gastric colonization and its pathogenicity. Toxins (Basel). 2019; 11 (11): е677. DOI: 10.3390/toxins11110677.
  52. Minaga K, Watanabe T, Kamata K, Asano N, Kudo M. Nucleotide-binding oligomerization domain 1 and Helicobacter pylori infection: A review. World J Gastroenterol. 2018; 24 (16): 1725–33. DOI: 10.3748/wjg.v24.i16.1725.
  53. Grohmann E, Christie PJ, Waksman G, Backert S. Type IV secretion in Gram-negative and Gram-positive bacteria. Mol Microbiol. 2018; 107 (4): 455–71. DOI: 10.1111/mmi.13896.
  54. Ye W, Held M, Lagergren J, Engstrand L, Blot WJ, McLaughlin JK, Nyrén O. Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer Inst. 2004; 96 (5): 388–96. DOI: 10.1093/jnci/djh057.
  55. Hu Z, Zhang Y, Li Z, Yu Y, Kang W, Han Y, et al. Effect of Helicobacter pylori infection on chronic periodontitis by the change of microecology and inflammation. Oncotarget. 2016; 7 (41): 66700–12. DOI: 10.18632/oncotarget.
  56. Guraya SY, Ahmad AA, El-Ageery SM, Hemeg HA, Ozbak HA, Yousef K, et al. The correlation of Helicobacter pylori with the development of cholelithiasis and cholecystitis: the results of a prospective clinical study in Saudi Arabia. Eur Rev Med Pharmacol Sci. 2015; 19 (20): 3873–80.
  57. Yang F, Xu Y-L, Zhu R-F. Helicobacter pylori infection and the risk of colorectal carcinoma: a systematic review and meta-analysis. Minerva Med. 2019; 110 (5): 464–70. DOI: 10.23736/S0026-4806.19.05942-1.
  58. Ryoo SK, Kim TJ, Kim ER, Hong SN, Kim Y-H, Chang DK. Helicobacter pylori Infection and the development of advanced colorectal neoplasia. J Clin Gastroenterol. 2020; 54 (8): 696–700. DOI: 10.1097/MCG.0000000000001273.
  59. Toledo R, Fried B, editors. Digenetic trematodes. Advances in Experimental Medicine and Biology. Vol. 766. New-York: Springer, 2014; 474 p.
  60. Lim MK, Ju YH, Franceschi S, Oh JK, Kong HJ, Hwang SS, et al. Clonorchis sinensis infection and increasing risk of cholangiocarcinoma in the Republic of Korea. Am J Trop Med Hyg. 2006; 75 (1): 93–6. DOI: 10.4269/ajtmh.2006.75.93.
  61. Shin HR, Oh JK, Masuyer E, Curado MP, Bouvard V, Fang YY, et al. Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci. 2010; 101 (3): 579–85. DOI: 10.1111/j.1349-7006.2009.01458.x.
  62. WHO. International Agency for Research on Cancer IARC Biological agents. A review of human carcinogens. IARC monographs on the evaluation of carcinogenic risks to humans; 2012; 100B; 100: 441. DOI: 10.4135/9781412963855.n637.
  63. Omarova HG, Aleshina NI, Ponezheva ZhB. Riski onkologicheskoj patologii pri parazitozah v nastojashhee vremja. Terapevticheskij arhiv. 2020; 92 (11): 82–5 (in Rus.). DOI: 10.26442/00403660.2020.11.000710.
  64. Prohorov BB. Zabolevaemost' naselenija. Infekcionnye bolezni: biogel'mintozy. Opistorhoz. V jel. versii atlasa "Okruzhajushhaja sreda i zdorov'e naselenija Rossii". (In Rus.). Available from: http://www. sci.aha.ru/ ATL/ra55g.htm.
  65. Fedorova OS, Kovshirina JuV, Kovshirina AE, Fedotova MM, Deev IA, Petrovskij FI, et al. Analiz zabolevaemosti invaziej Opisthorchis felineus i zlokachestvennymi novoobrazovanijami gepatobiliarnoj sistemy v Rossijskoj Federacii. Bjulleten' sibirskoj mediciny. 2016; 15 (5): 67–78 (in Rus.).
  66. Kokaliaris C, Garba A, Matuska M, Bronzan RN, Colley DG, Dorkenoo AM, et al. Effect of preventive chemotherapy with praziquantel on schistosomiasis among school-aged children in sub-Saharan Africa: a spatiotemporal modelling study. Lancet Infect Dis. 2022; 22 (1): 136–49. DOI: 10.1016/S1473-3099(21)00090-6.
  67. Schistosomiasis. WHO recommendations, updated February 2014. Available from: http://www.who.int/mediacentre/factsheets/fs115/en.
  68. Starcev VJu, Kolmakov AJu. Jekologo-diagnosticheskie aspekty mochepolovogo shistosomoza kak predrakovogo zabolevanija (obzor literatury). Jekologija cheloveka. 2016; (1): 50–6 (in Rus.).
  69. Asfandijarov FR, Starcev VJu, Kolmakov AJu. Vozmozhnosti diagnostiki i lechenija mochepolovogo shistosomatoza v sovremennyh uslovijah. Vestnik urologii. 2018; 6 (3): 5–11 (in Rus.). DOI: 10.21886/2308-6424-2017-6-3-5-11.
  70. Kolmakov AJu, Starcev VJu. Ploskokletochnaja metaplazija kak projavlenie mochepolovogo shistosomoza i ego oslozhnenij. Onkourologija. 2016; 12 (2): 58–63 (in Rus.). DOI: 10.17650/1726-9776-2016-12-2-58-63.
  71. de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012; 13 (6): 607–15. DOI: 10.1016/S1470-2045(12)70137-7.
  72. Fried B, Reddy A, Mayer D. Helminths in human carcinogenesis. Cancer Lett. 2011; 305 (2): 239–49. DOI: 10.1016/j.canlet.2010.07.008.
  73. Vennervald BJ, Polman K. Helminths and malignancy. Parasite Immunol. 2009; 31 (11): 686–96. DOI: 10.1111/j.1365-3024.2009.01163.x.
  74. Fulbright LE, Ellermann M, Arthur JC. The microbiome and the hallmarks of cancer. PLoS Pathog. 2017; 13 (9): e1006480. DOI: 10.1371/journal.ppat.
  75. Garrett WS. Cancer and the microbiota. Science (New York, NY). 2015; 348 (6230): 80–6. DOI: 10.1126/science.aaa4972.
  76. Leung JM, Graham AL, Knowles SCL. Parasite-microbiota interactions with the vertebrate gut: synthesis through an ecological lens. Front Microbiol. 2018; (9): 843. DOI: 10.3389/fmicb.2018.0084317–20.